The linearly decreasing convergence factor a. حسب Junhao Wei (6816803)

Study-related adverse events. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Study flow chart. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Study CONSORT diagram. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Overview of the WeARTolerance program. حسب Ana Beato (20489933)

الموضوعات:

Study selection criteria. حسب Filip Stanicic (17808254)

الموضوعات:

PICOS criteria for the SLR. حسب Filip Stanicic (17808254)

الموضوعات:

PRISMA flow chart. حسب Filip Stanicic (17808254)

الموضوعات:

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Primary and secondary efficacy end points (intention-to-treat population). حسب Benjamin R. Lewis (22279166)

الموضوعات:

Demographic and clinical characteristics of participants at baseline. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Change in Demoralization Scale (DSII) by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Bluetooth beacons with colour coded lanyards. حسب J Mark Ansermino (13958512)

الموضوعات:

Brain regions with significantly decreased activations for the Raven task are shown in blue. حسب Morteza Fattahi (15892028)

Larger example of stimuli with cue relevant for Task 3. حسب Marcel F. Hinss (14675457)